|
1
|
Wadhera RK, Steen DL, Khan I, Giugliano RP
and Foody JM: A review of low-density lipoprotein cholesterol,
treatment strategies, and its impact on cardiovascular disease
morbidity and mortality. J Clin Lipidol. 10:472–489.
2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Stone NJ, Robinson JG, Lichtenstein AH,
Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D,
Lloyd-Jones DM, et al: American College of Cardiology/American
Heart Association Task Force on Practice Guidelines: 2013 ACC/AHA
guideline on the treatment of blood cholesterol to reduce
atherosclerotic cardiovascular risk in adults: A report of the
American College of Cardiology/American Heart Association Task
Force on Practice Guidelines. Circulation. 129 (Suppl 2):S1–S45.
2014.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Grundy SM, Arai H, Barter P, Bersot TP,
Betteridge DJ, Carmena R, Cuevas A, Davidson MH, Genest J,
Kesäniemi YA, et al: Expert Dyslipidemia Panel of the International
Atherosclerosis Society Panel members: An International
Atherosclerosis Society Position Paper: Global recommendations for
the management of dyslipidemia - full report. J Clin Lipidol.
8:29–60. 2014.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Li H, Dong B, Park SW, Lee HS, Chen W and
Liu J: Hepatocyte nuclear factor 1alpha plays a critical role in
PCSK9 gene transcription and regulation by the natural
hypocholesterolemic compound berberine. J Biol Chem.
284:28885–28895. 2009.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Zhang DW, Garuti R, Tang WJ, Cohen JC and
Hobbs HH: Structural requirements for PCSK9-mediated degradation of
the low-density lipoprotein receptor. Proc Natl Acad Sci USA.
105:13045–13050. 2008.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kesaniemi YA, Witztum JL and Steinbrecher
UP: Receptor-mediated catabolism of low density lipoprotein in man.
Quantitation using glucosylated low density lipoprotein. J Clin
Invest. 71:950–959. 1983.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Brown MS and Goldstein JL: A
receptor-mediated pathway for cholesterol homeostasis. Science.
232:34–47. 1986.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Lo Surdo P, Bottomley MJ, Calzetta A,
Settembre EC, Cirillo A, Pandit S, Ni YG, Hubbard B, Sitlani A and
Carfí A: Mechanistic implications for LDL receptor degradation from
the PCSK9/LDLR structure at neutral pH. EMBO Rep. 12:1300–1305.
2011.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Goldstein JL and Brown MS: A century of
cholesterol and coronaries: From plaques to genes to statins. Cell.
161:161–172. 2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Südhof TC, Van der Westhuyzen DR,
Goldstein JL, Brown MS and Russell DW: Three direct repeats and a
TATA-like sequence are required for regulated expression of the
human low density lipoprotein receptor gene. J Biol Chem.
262:10773–10779. 1987.PubMed/NCBI
|
|
11
|
Miserez AR, Muller PY, Barella L, Barella
S, Staehelin HB, Leitersdorf E, Kark JD and Friedlander Y:
Sterol-regulatory element-binding protein (SREBP)-2 contributes to
polygenic hypercholesterolaemia. Atherosclerosis. 164:15–26.
2002.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Wilson GM, Vasa MZ and Deeley RG:
Stabilization and cytoskeletal-association of LDL receptor mRNA are
mediated by distinct domains in its 3' untranslated region. J Lipid
Res. 39:1025–1032. 1998.PubMed/NCBI
|
|
13
|
Zhang T, Kruys V, Huez G and Gueydan C:
AU-rich element-mediated translational control: complexity and
multiple activities of trans-activating factors. Biochem Soc Trans.
30:952–958. 2002.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kong W, Wei J, Abidi P, Lin M, Inaba S, Li
C, Wang Y, Wang Z, Si S, Pan H, et al: Berberine is a novel
cholesterol-lowering drug working through a unique mechanism
distinct from statins. Nat Med. 10:1344–1351. 2004.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Yashiro T, Yokoi Y, Shimizu M, Inoue J and
Sato R: Chenodeoxycholic acid stabilization of LDL receptor mRNA
depends on 3'-untranslated region and AU-rich element-binding
protein. Biochem Biophys Res Commun. 409:155–159. 2011.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Li Z, Jiang JD and Kong WJ: Berberine
up-regulates hepatic low-density lipoprotein receptor through
Ras-independent but AMP-activated protein kinase-dependent Raf-1
activation. Biol Pharm Bull. 37:1766–1775. 2014.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Zhang CP, Tian Y, Zhang M, Tuo QH, Chen JX
and Liao DF: IDOL, inducible degrader of low-density lipoprotein
receptor, serves as a potential therapeutic target for
dyslipidemia. Med Hypotheses. 86:138–142. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Tavori H, Fan D, Blakemore JL, Yancey PG,
Ding L, Linton MF and Fazio S: Serum proprotein convertase
subtilisin/kexin type 9 and cell surface low-density lipoprotein
receptor: Evidence for a reciprocal regulation. Circulation.
127:2403–2413. 2013.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Abifadel M, Varret M, Rabès JP, Allard D,
Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich
D, et al: Mutations in PCSK9 cause autosomal dominant
hypercholesterolemia. Nat Genet. 34:154–156. 2003.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Horton JD, Cohen JC and Hobbs HH: PCSK9: A
convertase that coordinates LDL catabolism. J Lipid Res. 50
(Suppl):S172–S177. 2009.PubMed/NCBI View Article : Google Scholar
|
|
21
|
McNutt MC, Kwon HJ, Chen C, Chen JR,
Horton JD and Lagace TA: Antagonism of secreted PCSK9 increases low
density lipoprotein receptor expression in HepG2 cells. J Biol
Chem. 284:10561–10570. 2009.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Raal FJ, Stein EA, Dufour R, Turner T,
Civeira F, Burgess L, Langslet G, Scott R, Olsson AG, Sullivan D,
et al: RUTHERFORD-2 Investigators: PCSK9 inhibition with evolocumab
(AMG 145) in heterozygous familial hypercholesterolaemia
(RUTHERFORD-2): A randomised, double-blind, placebo-controlled
trial. Lancet. 385:331–340. 2015.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Robinson JG, Farnier M, Krempf M, Bergeron
J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M,
et al: ODYSSEY LONG TERM Investigators: Efficacy and safety of
alirocumab in reducing lipids and cardiovascular events. N Engl J
Med. 372:1489–1499. 2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Li J, Li HH, Wang WQ, Song WB, Wang YP and
Xuan LJ: Jatrophane diterpenoids from Euphorbia helioscopia and
their lipid-lowering activities. Fitoterapia. 128:102–111.
2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Yamamura S, Shizuri Y, Kosemura S, Ohtsuka
J, Tayama T, Ohba S, Ito M, Saito Y and Terada Y: Diterpenes from
Euphorbia helioscopia. Phytochemistry. 28:3421–3436. 1989.
|
|
26
|
World Med A; World Medical Association.
World Medical Association Declaration of Helsinki: Ethical
principles for medical research involving human subjects. JAMA.
310:2191–2194. 2013.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Stephan ZF and Yurachek EC: Rapid
fluorometric assay of LDL receptor activity by DiI-labeled LDL. J
Lipid Res. 34:325–330. 1993.PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Sobell HM: Actinomycin and DNA
transcription. Proc Natl Acad Sci USA. 82:5328–5331.
1985.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Greenfield EA: Administering anesthesia to
mice, rats, and hamsters. Cold Spring Harb Protoc: Jun 3, 2019.
doi: 10.1101/pdb.prot100198.
|
|
31
|
Smith AJ, Clutton RE, Lilley E, Hansen KEA
and Brattelid T: PREPARE: Guidelines for planning animal research
and testing. Lab Anim. 52:135–141. 2018.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Dong B, Young M, Liu X, Singh AB and Liu
J: Regulation of lipid metabolism by obeticholic acid in
hyperlipidemic hamsters. J Lipid Res. 58:350–363. 2017.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Dong B, Li H, Singh AB, Cao A and Liu J:
Inhibition of PCSK9 transcription by berberine involves
down-regulation of hepatic HNF1α protein expression through the
ubiquitin-proteasome degradation pathway. J Biol Chem.
290:4047–4058. 2015.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Barreau C, Paillard L and Osborne HB:
AU-rich elements and associated factors: Are there unifying
principles? Nucleic Acids Res. 33:7138–7150. 2006.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Wilusz CJ and Wilusz J: Bringing the role
of mRNA decay in the control of gene expression into focus. Trends
Genet. 20:491–497. 2004.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Adachi S, Homoto M, Tanaka R, Hioki Y,
Murakami H, Suga H, Matsumoto M, Nakayama KI, Hatta T, Iemura S, et
al: ZFP36L1 and ZFP36L2 control LDLR mRNA stability via the ERK-RSK
pathway. Nucleic Acids Res. 42:10037–10049. 2014.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Yashiro T, Nanmoku M, Shimizu M, Inoue J
and Sato R: 5-Aminoimidazole-4-carboxamide ribonucleoside
stabilizes low density lipoprotein receptor mRNA in hepatocytes via
ERK-dependent HuR binding to an AU-rich element. Atherosclerosis.
226:95–101. 2013.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Zhang Q, Meng F, Chen S, Plouffe SW, Wu S,
Liu S, Li X, Zhou R, Wang J, Zhao B, et al: Hippo signalling
governs cytosolic nucleic acid sensing through YAP/TAZ-mediated
TBK1 blockade. Nat Cell Biol. 19:362–374. 2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Miller E, Antonny B, Hamamoto S and
Schekman R: Cargo selection into COPII vesicles is driven by the
Sec24p subunit. EMBO J. 21:6105–6113. 2002.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Emmer BT, Hesketh GG, Kotnik E, Tang VT,
Lascuna PJ, Xiang J, Gingras AC, Chen XW and Ginsburg D: The cargo
receptor SURF4 promotes the efficient cellular secretion of PCSK9.
eLife. 7(7)2018.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Willnow TE, Petersen CM and Nykjaer A:
VPS10P-domain receptors - regulators of neuronal viability and
function. Nat Rev Neurosci. 9:899–909. 2008.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Kathiresan S, Melander O, Guiducci C,
Surti A, Burtt NP, Rieder MJ, Cooper GM, Roos C, Voight BF,
Havulinna AS, et al: Six new loci associated with blood low-density
lipoprotein cholesterol, high-density lipoprotein cholesterol or
triglycerides in humans. Nat Genet. 40:189–197. 2008.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Linsel-Nitschke P, Heeren J, Aherrahrou Z,
Bruse P, Gieger C, Illig T, Prokisch H, Heim K, Doering A, Peters
A, et al: Genetic variation at chromosome 1p13.3 affects sortilin
mRNA expression, cellular LDL-uptake and serum LDL levels which
translates to the risk of coronary artery disease. Atherosclerosis.
208:183–189. 2010.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Gustafsen C, Kjolby M, Nyegaard M,
Mattheisen M, Lundhede J, Buttenschøn H, Mors O, Bentzon JF, Madsen
P, Nykjaer A, et al: The hypercholesterolemia-risk gene SORT1
facilitates PCSK9 secretion. Cell Metab. 19:310–318.
2014.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Chen C, Li J, Matye DJ, Wang Y and Li T:
Hepatocyte sortilin 1 knockout and treatment with a sortilin 1
inhibitor reduced plasma cholesterol in Western diet-fed mice. J
Lipid Res. 60:539–549. 2019.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Barile E, Borriello M, Di Pietro A, Doreau
A, Fattorusso C, Fattorusso E and Lanzotti V: Discovery of a new
series of jatrophane and lathyrane diterpenes as potent and
specific P-glycoprotein modulators. Org Biomol Chem. 6:1756–1762.
2008.PubMed/NCBI View Article : Google Scholar
|
